nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT2B7—Ezetimibe—atherosclerosis	0.147	0.19	CbGbCtD
Dapagliflozin—UGT2B7—Simvastatin—atherosclerosis	0.136	0.177	CbGbCtD
Dapagliflozin—UGT2B7—Lovastatin—atherosclerosis	0.134	0.173	CbGbCtD
Dapagliflozin—CYP2D6—Niacin—atherosclerosis	0.0279	0.0361	CbGbCtD
Dapagliflozin—CYP2C9—Rosuvastatin—atherosclerosis	0.0259	0.0335	CbGbCtD
Dapagliflozin—ABCB1—Ezetimibe—atherosclerosis	0.0252	0.0325	CbGbCtD
Dapagliflozin—CYP2C9—Simvastatin—atherosclerosis	0.0241	0.0312	CbGbCtD
Dapagliflozin—CYP2C9—Pravastatin—atherosclerosis	0.0236	0.0305	CbGbCtD
Dapagliflozin—CYP2C9—Lovastatin—atherosclerosis	0.0236	0.0305	CbGbCtD
Dapagliflozin—ABCB1—Simvastatin—atherosclerosis	0.0234	0.0303	CbGbCtD
Dapagliflozin—ABCB1—Lovastatin—atherosclerosis	0.0229	0.0296	CbGbCtD
Dapagliflozin—ABCB1—Pravastatin—atherosclerosis	0.0229	0.0296	CbGbCtD
Dapagliflozin—CYP2D6—Simvastatin—atherosclerosis	0.022	0.0285	CbGbCtD
Dapagliflozin—CYP2D6—Pravastatin—atherosclerosis	0.0216	0.0279	CbGbCtD
Dapagliflozin—CYP2D6—Lovastatin—atherosclerosis	0.0216	0.0279	CbGbCtD
Dapagliflozin—CYP3A4—Rosuvastatin—atherosclerosis	0.0151	0.0195	CbGbCtD
Dapagliflozin—CYP3A4—Ezetimibe—atherosclerosis	0.0151	0.0195	CbGbCtD
Dapagliflozin—CYP3A4—Simvastatin—atherosclerosis	0.014	0.0181	CbGbCtD
Dapagliflozin—CYP3A4—Pravastatin—atherosclerosis	0.0137	0.0177	CbGbCtD
Dapagliflozin—CYP3A4—Lovastatin—atherosclerosis	0.0137	0.0177	CbGbCtD
Dapagliflozin—Dyslipidaemia—Pravastatin—atherosclerosis	0.00943	0.106	CcSEcCtD
Dapagliflozin—Lung disorder—Niacin—atherosclerosis	0.00209	0.0236	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00198	0.0224	CcSEcCtD
Dapagliflozin—Canagliflozin—ALB—atherosclerosis	0.00189	1	CrCbGaD
Dapagliflozin—Diabetes mellitus—Rosuvastatin—atherosclerosis	0.0017	0.0192	CcSEcCtD
Dapagliflozin—Nocturia—Pravastatin—atherosclerosis	0.00157	0.0177	CcSEcCtD
Dapagliflozin—Vaginal infection—Niacin—atherosclerosis	0.0014	0.0158	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Simvastatin—atherosclerosis	0.00135	0.0152	CcSEcCtD
Dapagliflozin—Urine output increased—Niacin—atherosclerosis	0.00134	0.0151	CcSEcCtD
Dapagliflozin—Influenza—Rosuvastatin—atherosclerosis	0.00128	0.0144	CcSEcCtD
Dapagliflozin—Pain in extremity—Lovastatin—atherosclerosis	0.00125	0.0141	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Niacin—atherosclerosis	0.00124	0.014	CcSEcCtD
Dapagliflozin—Pain in extremity—Ezetimibe—atherosclerosis	0.00123	0.0139	CcSEcCtD
Dapagliflozin—Polyuria—Niacin—atherosclerosis	0.00122	0.0138	CcSEcCtD
Dapagliflozin—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00111	0.0125	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Ezetimibe—atherosclerosis	0.0011	0.0124	CcSEcCtD
Dapagliflozin—Influenza—Lovastatin—atherosclerosis	0.00108	0.0122	CcSEcCtD
Dapagliflozin—Influenza—Ezetimibe—atherosclerosis	0.00106	0.012	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Niacin—atherosclerosis	0.000982	0.0111	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Pravastatin—atherosclerosis	0.000946	0.0107	CcSEcCtD
Dapagliflozin—Infestation—Ezetimibe—atherosclerosis	0.000946	0.0107	CcSEcCtD
Dapagliflozin—Infestation NOS—Ezetimibe—atherosclerosis	0.000946	0.0107	CcSEcCtD
Dapagliflozin—Urinary tract infection—Lovastatin—atherosclerosis	0.000937	0.0106	CcSEcCtD
Dapagliflozin—Influenza—Niacin—atherosclerosis	0.000929	0.0105	CcSEcCtD
Dapagliflozin—Influenza—Pravastatin—atherosclerosis	0.000915	0.0103	CcSEcCtD
Dapagliflozin—Angina pectoris—Niacin—atherosclerosis	0.000905	0.0102	CcSEcCtD
Dapagliflozin—Angina pectoris—Pravastatin—atherosclerosis	0.000891	0.0101	CcSEcCtD
Dapagliflozin—Dysuria—Pravastatin—atherosclerosis	0.000855	0.00966	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000834	0.00942	CcSEcCtD
Dapagliflozin—Angioedema—Rosuvastatin—atherosclerosis	0.000813	0.00918	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000804	0.00908	CcSEcCtD
Dapagliflozin—Myocardial infarction—Pravastatin—atherosclerosis	0.000799	0.00903	CcSEcCtD
Dapagliflozin—Urinary tract infection—Pravastatin—atherosclerosis	0.000793	0.00895	CcSEcCtD
Dapagliflozin—Malnutrition—Ezetimibe—atherosclerosis	0.000739	0.00835	CcSEcCtD
Dapagliflozin—Back pain—Lovastatin—atherosclerosis	0.000729	0.00823	CcSEcCtD
Dapagliflozin—Infection—Rosuvastatin—atherosclerosis	0.000721	0.00814	CcSEcCtD
Dapagliflozin—Back pain—Ezetimibe—atherosclerosis	0.000715	0.00807	CcSEcCtD
Dapagliflozin—Angioedema—Lovastatin—atherosclerosis	0.000689	0.00778	CcSEcCtD
Dapagliflozin—Angioedema—Ezetimibe—atherosclerosis	0.000675	0.00763	CcSEcCtD
Dapagliflozin—Malnutrition—Niacin—atherosclerosis	0.000647	0.00731	CcSEcCtD
Dapagliflozin—Angioedema—Simvastatin—atherosclerosis	0.000644	0.00727	CcSEcCtD
Dapagliflozin—Hypertension—Ezetimibe—atherosclerosis	0.000638	0.00721	CcSEcCtD
Dapagliflozin—Discomfort—Lovastatin—atherosclerosis	0.000634	0.00716	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000625	0.00706	CcSEcCtD
Dapagliflozin—Discomfort—Ezetimibe—atherosclerosis	0.000622	0.00702	CcSEcCtD
Dapagliflozin—Constipation—Rosuvastatin—atherosclerosis	0.000621	0.00701	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Lovastatin—atherosclerosis	0.000615	0.00695	CcSEcCtD
Dapagliflozin—Infection—Lovastatin—atherosclerosis	0.000611	0.0069	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000603	0.00681	CcSEcCtD
Dapagliflozin—Infection—Ezetimibe—atherosclerosis	0.000599	0.00677	CcSEcCtD
Dapagliflozin—Discomfort—Simvastatin—atherosclerosis	0.000593	0.0067	CcSEcCtD
Dapagliflozin—Angioedema—Niacin—atherosclerosis	0.000591	0.00668	CcSEcCtD
Dapagliflozin—Skin disorder—Ezetimibe—atherosclerosis	0.000586	0.00662	CcSEcCtD
Dapagliflozin—Angioedema—Pravastatin—atherosclerosis	0.000582	0.00658	CcSEcCtD
Dapagliflozin—Urticaria—Rosuvastatin—atherosclerosis	0.000577	0.00651	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Simvastatin—atherosclerosis	0.000575	0.0065	CcSEcCtD
Dapagliflozin—Oedema—Simvastatin—atherosclerosis	0.000575	0.0065	CcSEcCtD
Dapagliflozin—Infection—Simvastatin—atherosclerosis	0.000572	0.00645	CcSEcCtD
Dapagliflozin—Hypertension—Pravastatin—atherosclerosis	0.00055	0.00621	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000547	0.00618	CcSEcCtD
Dapagliflozin—Discomfort—Pravastatin—atherosclerosis	0.000536	0.00605	CcSEcCtD
Dapagliflozin—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000535	0.00604	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Niacin—atherosclerosis	0.000528	0.00597	CcSEcCtD
Dapagliflozin—Oedema—Niacin—atherosclerosis	0.000528	0.00597	CcSEcCtD
Dapagliflozin—Constipation—Lovastatin—atherosclerosis	0.000526	0.00594	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000521	0.00588	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Pravastatin—atherosclerosis	0.00052	0.00587	CcSEcCtD
Dapagliflozin—Oedema—Pravastatin—atherosclerosis	0.00052	0.00587	CcSEcCtD
Dapagliflozin—Infection—Pravastatin—atherosclerosis	0.000517	0.00584	CcSEcCtD
Dapagliflozin—Constipation—Ezetimibe—atherosclerosis	0.000516	0.00583	CcSEcCtD
Dapagliflozin—Skin disorder—Niacin—atherosclerosis	0.000513	0.00579	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Niacin—atherosclerosis	0.000511	0.00577	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Pravastatin—atherosclerosis	0.000503	0.00568	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000497	0.00561	CcSEcCtD
Dapagliflozin—Hypotension—Niacin—atherosclerosis	0.000494	0.00557	CcSEcCtD
Dapagliflozin—Constipation—Simvastatin—atherosclerosis	0.000492	0.00556	CcSEcCtD
Dapagliflozin—Urticaria—Lovastatin—atherosclerosis	0.000489	0.00552	CcSEcCtD
Dapagliflozin—Body temperature increased—Lovastatin—atherosclerosis	0.000486	0.00549	CcSEcCtD
Dapagliflozin—Dizziness—Rosuvastatin—atherosclerosis	0.00048	0.00542	CcSEcCtD
Dapagliflozin—Urticaria—Ezetimibe—atherosclerosis	0.000479	0.00541	CcSEcCtD
Dapagliflozin—Body temperature increased—Ezetimibe—atherosclerosis	0.000477	0.00539	CcSEcCtD
Dapagliflozin—Rash—Rosuvastatin—atherosclerosis	0.000458	0.00517	CcSEcCtD
Dapagliflozin—Dermatitis—Rosuvastatin—atherosclerosis	0.000457	0.00516	CcSEcCtD
Dapagliflozin—Urticaria—Simvastatin—atherosclerosis	0.000457	0.00516	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Niacin—atherosclerosis	0.000456	0.00515	CcSEcCtD
Dapagliflozin—Body temperature increased—Simvastatin—atherosclerosis	0.000455	0.00514	CcSEcCtD
Dapagliflozin—Headache—Rosuvastatin—atherosclerosis	0.000455	0.00513	CcSEcCtD
Dapagliflozin—Hypersensitivity—Lovastatin—atherosclerosis	0.000453	0.00512	CcSEcCtD
Dapagliflozin—Constipation—Pravastatin—atherosclerosis	0.000445	0.00502	CcSEcCtD
Dapagliflozin—Hypersensitivity—Ezetimibe—atherosclerosis	0.000445	0.00502	CcSEcCtD
Dapagliflozin—Nausea—Rosuvastatin—atherosclerosis	0.000431	0.00487	CcSEcCtD
Dapagliflozin—Hypersensitivity—Simvastatin—atherosclerosis	0.000424	0.00479	CcSEcCtD
Dapagliflozin—Urticaria—Niacin—atherosclerosis	0.00042	0.00474	CcSEcCtD
Dapagliflozin—Body temperature increased—Niacin—atherosclerosis	0.000418	0.00472	CcSEcCtD
Dapagliflozin—Urticaria—Pravastatin—atherosclerosis	0.000413	0.00467	CcSEcCtD
Dapagliflozin—Body temperature increased—Pravastatin—atherosclerosis	0.000411	0.00464	CcSEcCtD
Dapagliflozin—Dizziness—Lovastatin—atherosclerosis	0.000407	0.00459	CcSEcCtD
Dapagliflozin—Dizziness—Ezetimibe—atherosclerosis	0.000399	0.00451	CcSEcCtD
Dapagliflozin—Hypersensitivity—Niacin—atherosclerosis	0.000389	0.0044	CcSEcCtD
Dapagliflozin—Rash—Lovastatin—atherosclerosis	0.000388	0.00438	CcSEcCtD
Dapagliflozin—Dermatitis—Lovastatin—atherosclerosis	0.000387	0.00438	CcSEcCtD
Dapagliflozin—Headache—Lovastatin—atherosclerosis	0.000385	0.00435	CcSEcCtD
Dapagliflozin—Hypersensitivity—Pravastatin—atherosclerosis	0.000383	0.00433	CcSEcCtD
Dapagliflozin—Dizziness—Simvastatin—atherosclerosis	0.00038	0.0043	CcSEcCtD
Dapagliflozin—Rash—Ezetimibe—atherosclerosis	0.00038	0.0043	CcSEcCtD
Dapagliflozin—Dermatitis—Ezetimibe—atherosclerosis	0.00038	0.00429	CcSEcCtD
Dapagliflozin—Headache—Ezetimibe—atherosclerosis	0.000378	0.00427	CcSEcCtD
Dapagliflozin—Nausea—Lovastatin—atherosclerosis	0.000365	0.00413	CcSEcCtD
Dapagliflozin—Rash—Simvastatin—atherosclerosis	0.000363	0.0041	CcSEcCtD
Dapagliflozin—Dermatitis—Simvastatin—atherosclerosis	0.000362	0.00409	CcSEcCtD
Dapagliflozin—Headache—Simvastatin—atherosclerosis	0.00036	0.00407	CcSEcCtD
Dapagliflozin—Nausea—Ezetimibe—atherosclerosis	0.000358	0.00405	CcSEcCtD
Dapagliflozin—Dizziness—Niacin—atherosclerosis	0.000349	0.00394	CcSEcCtD
Dapagliflozin—Dizziness—Pravastatin—atherosclerosis	0.000344	0.00388	CcSEcCtD
Dapagliflozin—Nausea—Simvastatin—atherosclerosis	0.000342	0.00386	CcSEcCtD
Dapagliflozin—Rash—Niacin—atherosclerosis	0.000333	0.00376	CcSEcCtD
Dapagliflozin—Dermatitis—Niacin—atherosclerosis	0.000333	0.00376	CcSEcCtD
Dapagliflozin—Headache—Niacin—atherosclerosis	0.000331	0.00374	CcSEcCtD
Dapagliflozin—Rash—Pravastatin—atherosclerosis	0.000328	0.0037	CcSEcCtD
Dapagliflozin—Dermatitis—Pravastatin—atherosclerosis	0.000328	0.0037	CcSEcCtD
Dapagliflozin—Headache—Pravastatin—atherosclerosis	0.000326	0.00368	CcSEcCtD
Dapagliflozin—Nausea—Niacin—atherosclerosis	0.000314	0.00354	CcSEcCtD
Dapagliflozin—Nausea—Pravastatin—atherosclerosis	0.000309	0.00349	CcSEcCtD
Dapagliflozin—CYP2D6—Metabolism—APOA5—atherosclerosis	1.25e-05	9.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.24e-05	9.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOA5—atherosclerosis	1.24e-05	9.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.24e-05	9.07e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALOX5—atherosclerosis	1.23e-05	9.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HMOX1—atherosclerosis	1.23e-05	9.03e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—APOE—atherosclerosis	1.22e-05	8.98e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP27A1—atherosclerosis	1.22e-05	8.95e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CAV1—atherosclerosis	1.21e-05	8.9e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—APOA1—atherosclerosis	1.21e-05	8.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.2e-05	8.82e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	1.2e-05	8.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.2e-05	8.81e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HMGCR—atherosclerosis	1.2e-05	8.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	1.19e-05	8.74e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.19e-05	8.7e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ALB—atherosclerosis	1.18e-05	8.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOB—atherosclerosis	1.18e-05	8.65e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.18e-05	8.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.17e-05	8.6e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.17e-05	8.56e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.16e-05	8.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALOX5—atherosclerosis	1.16e-05	8.52e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALOX15—atherosclerosis	1.16e-05	8.49e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	1.16e-05	8.49e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	1.16e-05	8.49e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOA2—atherosclerosis	1.16e-05	8.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALOX5—atherosclerosis	1.15e-05	8.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTM1—atherosclerosis	1.15e-05	8.42e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCG5—atherosclerosis	1.14e-05	8.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.14e-05	8.37e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—atherosclerosis	1.14e-05	8.36e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NOS3—atherosclerosis	1.13e-05	8.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—LPL—atherosclerosis	1.13e-05	8.26e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.12e-05	8.24e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NAMPT—atherosclerosis	1.11e-05	8.11e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CG—atherosclerosis	1.11e-05	8.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LPA—atherosclerosis	1.1e-05	8.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GPX1—atherosclerosis	1.1e-05	8.06e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—LIPC—atherosclerosis	1.1e-05	8.06e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOC3—atherosclerosis	1.09e-05	8.01e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—LDLR—atherosclerosis	1.08e-05	7.96e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.08e-05	7.94e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CD36—atherosclerosis	1.07e-05	7.85e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCA1—atherosclerosis	1.07e-05	7.84e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BGN—atherosclerosis	1.07e-05	7.84e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARG—atherosclerosis	1.07e-05	7.82e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.06e-05	7.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.06e-05	7.78e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CETP—atherosclerosis	1.06e-05	7.77e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOA5—atherosclerosis	1.06e-05	7.76e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LCAT—atherosclerosis	1.06e-05	7.75e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—FABP4—atherosclerosis	1.06e-05	7.75e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—INS—atherosclerosis	1.05e-05	7.67e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NAMPT—atherosclerosis	1.04e-05	7.64e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.04e-05	7.63e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOA4—atherosclerosis	1.04e-05	7.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—LIPC—atherosclerosis	1.03e-05	7.59e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—atherosclerosis	1.03e-05	7.57e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NAMPT—atherosclerosis	1.03e-05	7.57e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOC3—atherosclerosis	1.03e-05	7.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.03e-05	7.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.03e-05	7.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—LIPC—atherosclerosis	1.03e-05	7.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—LDLR—atherosclerosis	1.02e-05	7.5e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOC3—atherosclerosis	1.02e-05	7.48e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.02e-05	7.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	1.02e-05	7.47e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SCARB1—atherosclerosis	1.01e-05	7.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MTHFR—atherosclerosis	1.01e-05	7.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—LDLR—atherosclerosis	1.01e-05	7.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.01e-05	7.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CETP—atherosclerosis	9.98e-06	7.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	9.98e-06	7.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	9.95e-06	7.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARA—atherosclerosis	9.95e-06	7.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CETP—atherosclerosis	9.9e-06	7.26e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALOX5—atherosclerosis	9.84e-06	7.22e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AGT—atherosclerosis	9.63e-06	7.07e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ALB—atherosclerosis	9.59e-06	7.04e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMGCR—atherosclerosis	9.58e-06	7.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SCARB1—atherosclerosis	9.56e-06	7.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SCARB1—atherosclerosis	9.48e-06	6.95e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOE—atherosclerosis	9.44e-06	6.92e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP27A1—atherosclerosis	9.42e-06	6.91e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	9.39e-06	6.89e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CAV1—atherosclerosis	9.35e-06	6.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOA1—atherosclerosis	9.33e-06	6.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	9.23e-06	6.77e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HMOX1—atherosclerosis	9.17e-06	6.73e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NOS3—atherosclerosis	9.17e-06	6.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	9.09e-06	6.67e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMGCR—atherosclerosis	9.03e-06	6.62e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMGCR—atherosclerosis	8.95e-06	6.57e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALOX15—atherosclerosis	8.93e-06	6.55e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOA2—atherosclerosis	8.93e-06	6.55e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	8.93e-06	6.55e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	8.93e-06	6.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NAMPT—atherosclerosis	8.82e-06	6.47e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCG5—atherosclerosis	8.82e-06	6.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOB—atherosclerosis	8.79e-06	6.45e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	8.77e-06	6.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LIPC—atherosclerosis	8.77e-06	6.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOC3—atherosclerosis	8.71e-06	6.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LDLR—atherosclerosis	8.66e-06	6.35e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—atherosclerosis	8.55e-06	6.27e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ABCA1—atherosclerosis	8.54e-06	6.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—atherosclerosis	8.52e-06	6.25e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LPA—atherosclerosis	8.52e-06	6.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CETP—atherosclerosis	8.46e-06	6.2e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—LPL—atherosclerosis	8.39e-06	6.16e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—atherosclerosis	8.39e-06	6.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BGN—atherosclerosis	8.25e-06	6.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—atherosclerosis	8.22e-06	6.03e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPX1—atherosclerosis	8.19e-06	6.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOA5—atherosclerosis	8.17e-06	5.99e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SCARB1—atherosclerosis	8.1e-06	5.94e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.07e-06	5.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—INS—atherosclerosis	8.06e-06	5.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCA1—atherosclerosis	8.05e-06	5.9e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCA1—atherosclerosis	7.98e-06	5.85e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CD36—atherosclerosis	7.97e-06	5.85e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.89e-06	5.79e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.86e-06	5.77e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMGCR—atherosclerosis	7.65e-06	5.61e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALOX5—atherosclerosis	7.59e-06	5.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—atherosclerosis	7.55e-06	5.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARA—atherosclerosis	7.41e-06	5.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—atherosclerosis	7.39e-06	5.42e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMOX1—atherosclerosis	7.33e-06	5.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AGT—atherosclerosis	7.18e-06	5.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NOS3—atherosclerosis	7.07e-06	5.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOE—atherosclerosis	7.03e-06	5.16e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOB—atherosclerosis	7.02e-06	5.15e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CAV1—atherosclerosis	6.97e-06	5.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOA1—atherosclerosis	6.95e-06	5.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMOX1—atherosclerosis	6.91e-06	5.07e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.9e-06	5.06e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMOX1—atherosclerosis	6.85e-06	5.02e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—atherosclerosis	6.83e-06	5.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCA1—atherosclerosis	6.82e-06	5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.81e-06	4.99e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LIPC—atherosclerosis	6.77e-06	4.96e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOC3—atherosclerosis	6.72e-06	4.93e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—LPL—atherosclerosis	6.7e-06	4.92e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LDLR—atherosclerosis	6.68e-06	4.9e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOB—atherosclerosis	6.61e-06	4.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOB—atherosclerosis	6.56e-06	4.81e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPX1—atherosclerosis	6.54e-06	4.8e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CETP—atherosclerosis	6.53e-06	4.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—atherosclerosis	6.47e-06	4.74e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—atherosclerosis	6.43e-06	4.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—atherosclerosis	6.38e-06	4.68e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CD36—atherosclerosis	6.37e-06	4.67e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—atherosclerosis	6.35e-06	4.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—LPL—atherosclerosis	6.32e-06	4.63e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—LPL—atherosclerosis	6.26e-06	4.59e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.25e-06	4.59e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPX1—atherosclerosis	6.16e-06	4.52e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—atherosclerosis	6.13e-06	4.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPX1—atherosclerosis	6.11e-06	4.48e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—atherosclerosis	6.03e-06	4.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—INS—atherosclerosis	6.01e-06	4.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CD36—atherosclerosis	6e-06	4.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CD36—atherosclerosis	5.95e-06	4.36e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARA—atherosclerosis	5.92e-06	4.34e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.9e-06	4.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMOX1—atherosclerosis	5.85e-06	4.29e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AGT—atherosclerosis	5.73e-06	4.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—atherosclerosis	5.69e-06	4.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—atherosclerosis	5.64e-06	4.14e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOE—atherosclerosis	5.62e-06	4.12e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOB—atherosclerosis	5.6e-06	4.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARA—atherosclerosis	5.58e-06	4.09e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CAV1—atherosclerosis	5.57e-06	4.08e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOA1—atherosclerosis	5.55e-06	4.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARA—atherosclerosis	5.53e-06	4.06e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—atherosclerosis	5.51e-06	4.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—atherosclerosis	5.45e-06	4e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AGT—atherosclerosis	5.4e-06	3.96e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AGT—atherosclerosis	5.36e-06	3.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LPL—atherosclerosis	5.35e-06	3.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOE—atherosclerosis	5.29e-06	3.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NOS3—atherosclerosis	5.27e-06	3.87e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.26e-06	3.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOE—atherosclerosis	5.25e-06	3.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CAV1—atherosclerosis	5.24e-06	3.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOA1—atherosclerosis	5.23e-06	3.84e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPX1—atherosclerosis	5.22e-06	3.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CAV1—atherosclerosis	5.2e-06	3.81e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—atherosclerosis	5.19e-06	3.81e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOA1—atherosclerosis	5.19e-06	3.81e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CD36—atherosclerosis	5.08e-06	3.73e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.07e-06	3.72e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—atherosclerosis	4.89e-06	3.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—atherosclerosis	4.82e-06	3.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.82e-06	3.53e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—INS—atherosclerosis	4.8e-06	3.52e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.78e-06	3.5e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—atherosclerosis	4.74e-06	3.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARA—atherosclerosis	4.73e-06	3.47e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—atherosclerosis	4.61e-06	3.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AGT—atherosclerosis	4.58e-06	3.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—atherosclerosis	4.57e-06	3.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—INS—atherosclerosis	4.52e-06	3.32e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.51e-06	3.31e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOE—atherosclerosis	4.48e-06	3.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—INS—atherosclerosis	4.48e-06	3.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CAV1—atherosclerosis	4.44e-06	3.26e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOA1—atherosclerosis	4.43e-06	3.25e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—atherosclerosis	4.4e-06	3.23e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOB—atherosclerosis	4.32e-06	3.17e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—atherosclerosis	4.22e-06	3.09e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NOS3—atherosclerosis	4.21e-06	3.09e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.21e-06	3.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—atherosclerosis	4.15e-06	3.04e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LPL—atherosclerosis	4.13e-06	3.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—atherosclerosis	4.11e-06	3.02e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—atherosclerosis	4.05e-06	2.97e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX1—atherosclerosis	4.03e-06	2.96e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NOS3—atherosclerosis	3.97e-06	2.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NOS3—atherosclerosis	3.93e-06	2.88e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CD36—atherosclerosis	3.92e-06	2.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—atherosclerosis	3.91e-06	2.87e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—atherosclerosis	3.85e-06	2.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—INS—atherosclerosis	3.83e-06	2.81e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.72e-06	2.73e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARA—atherosclerosis	3.65e-06	2.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.63e-06	2.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—atherosclerosis	3.6e-06	2.64e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AGT—atherosclerosis	3.53e-06	2.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—atherosclerosis	3.51e-06	2.58e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOE—atherosclerosis	3.46e-06	2.54e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CAV1—atherosclerosis	3.43e-06	2.52e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOA1—atherosclerosis	3.42e-06	2.51e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NOS3—atherosclerosis	3.36e-06	2.46e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—atherosclerosis	3.25e-06	2.38e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.12e-06	2.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—atherosclerosis	3.07e-06	2.25e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—atherosclerosis	3.01e-06	2.21e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—INS—atherosclerosis	2.96e-06	2.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—atherosclerosis	2.71e-06	1.99e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NOS3—atherosclerosis	2.59e-06	1.9e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—atherosclerosis	2.42e-06	1.78e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.37e-06	1.74e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—atherosclerosis	1.93e-06	1.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—atherosclerosis	1.82e-06	1.34e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—atherosclerosis	1.81e-06	1.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—atherosclerosis	1.54e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—atherosclerosis	1.19e-06	8.74e-06	CbGpPWpGaD
